Señales en vivo de FYB.DE | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:36):

Stats
Volumen de hoy	4 802.00
Volumen promedio	8 148.00
Capitalización de mercado	705.39M
EPS	€0 ( 2024-04-25 )
Próxima fecha de ganancias	( €0 ) 2024-05-28
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	8.46
ATR14	€0.0820 (0.21%)

Volumen Correlación

Largo: 0.06 (neutral)

Corto: 0.29 (neutral)

Signal:(57.427) Neutral

Formycon AG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Formycon AG Correlación - Moneda/Commodity

-0.41
( neutral )

0.00
( neutral )

-0.38
( neutral )

0.40
( neutral )

0.32
( neutral )

Formycon AG Finanzas

Annual	2022
Ingresos:	€42.50M
Beneficio Bruto:	€12.07M (28.41 %)
EPS:	€2.62

FY	2022
Ingresos:	€42.50M
Beneficio Bruto:	€12.07M (28.41 %)
EPS:	€2.62

FY	2021
Ingresos:	€36.97M
Beneficio Bruto:	€1.01M (2.72 %)
EPS:	€-1.225

FY	2020
Ingresos:	€34.23M
Beneficio Bruto:	€8.76M (25.60 %)
EPS:	€-0.539

Financial Reports:

No articles found.

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.